Literature DB >> 3304523

Controlled trial of occlusive dressings in healing chronic venous ulcers.

C M Backhouse, S D Blair, A P Savage, J Walton, C N McCollum.   

Abstract

Fifty-six patients with chronic venous ulcers present for a mean of 2.4 years were randomized to either a new occlusive hydrocolloid dressing (Granuflex, Squibb Surgicare) or a porous non-adherent dressing (N A, Johnson and Johnson). In all patients, dressings were applied beneath a standard graduated compression bandage. There was no difference between the two groups, with complete healing in 21 out of 28 (75 per cent) of occlusive dressing patients and 22 out of 28 (78 per cent) with N A dressings by 12 weeks. Careful graduated compression bandaging achieves healing even in the majority of so-called resistant chronic venous ulcers; there was no additional benefit from applying occlusive dressings which tend to be expensive.

Entities:  

Mesh:

Year:  1987        PMID: 3304523     DOI: 10.1002/bjs.1800740732

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  5 in total

1.  The role of oxygen-derived free radicals in the management of venous (varicose) ulceration: a new approach.

Authors:  A S Salim
Journal:  World J Surg       Date:  1991 Mar-Apr       Impact factor: 3.352

2.  Oxpentifylline treatment of venous leg ulcers.

Authors:  H Gajraj; A Jopp-McKay; M C Stacey
Journal:  BMJ       Date:  1990-06-30

3.  Sustained compression and healing of chronic venous ulcers.

Authors:  S D Blair; D D Wright; C M Backhouse; E Riddle; C N McCollum
Journal:  BMJ       Date:  1988-11-05

Review 4.  Dressings and topical agents for treating venous leg ulcers.

Authors:  Gill Norman; Maggie J Westby; Amber D Rithalia; Nikki Stubbs; Marta O Soares; Jo C Dumville
Journal:  Cochrane Database Syst Rev       Date:  2018-06-15

Review 5.  Publicly Reported Wound Healing Rates: The Fantasy and the Reality.

Authors:  Caroline E Fife; Kristen A Eckert; Marissa J Carter
Journal:  Adv Wound Care (New Rochelle)       Date:  2018-03-01       Impact factor: 4.730

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.